Shorla raises $35m via Series B to progress oncology product portfolio
Shorla Oncology has raised $35m in a Series B funding round to progress its oncology product portfolio.
Stay updated with breaking news from Sharon Cunningham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shorla Oncology has raised $35m in a Series B funding round to progress its oncology product portfolio.
Founded in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla has an advanced pipeline of innovative oncology drugs for rare, orphan and paediatric cancers
CAMBRIDGE, Mass., October 04, 2023--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland. The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
The following Garden City students earned recognition for academic excellence on the SUNY Cortland Dean’s List for the Spring 2023 semester: Sara Aquino (Childhd Early Childhd B6) Susan Asciutto (Inclusive Early Child Edu(B-2)) Alyssa Barone (Business Economics) Hannah Barry (Criminology) Sophia Boccio (Biochemistry) Ella Marchignoli (Exercise Science) Megan Stabile (Communication Studies) Bianca Trunfio (Adolescence Educ-Math)